Effect of Cabergoline on Weight and Glucose Tolerance

Phase 1

Completed

• Conditions: Body Weight; Impaired Glucose Tolerance in Obese
• Interventions: Other: placebo; Drug: Cabergoline

• Registration Number: NCT01395602
• Lead Sponsor: Columbia University

Brief Summary

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.

This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.

The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-04
• Primary Completion: 2003-09
• Study Completion: 2011-07
• Study First Submitted: 2011-07-14
• Study First Submitted QC: 2011-07-14
• Study First Posted: 2011-07-15
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-13
• Last Update Posted: 2015-10-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• age 18 - 55 years
• BMI 30 -40

Exclusion Criteria

• diabetes,
• clinically significant medical condition,
• use of medications that effect blood glucose or body weight

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
placebo	placebo	placebo pill
cabergoline	Cabergoline	cabergoline pill

Primary Outcome Measures

Name	Time	Method
body weight	16 weeks

Secondary Outcome Measures

Name	Time	Method
glucose	16 weeks

Trial Locations

Locations (1)

Columbia University; 🇺🇸 New York, New York, United States